HALO HALOZYME THERAPEUTICS, INC.

Nasdaq halozyme.com


$ 65.72 $ 1.10 (1.69 %)    

Monday, 03-Nov-2025 19:37:06 EST
QQQ $ 629.78 $ -3.11 (-0.49 %)
DIA $ 472.70 $ -2.66 (-0.56 %)
SPY $ 681.88 $ -2.29 (-0.33 %)
TLT $ 89.68 $ 0.07 (0.08 %)
GLD $ 366.72 $ 0.05 (0.01 %)
$ 66.2
$ 65.13
$ 63.85 x 1
$ 67.27 x 55
$ 64.72 - $ 66.38
$ 42.01 - $ 79.50
2,752,521
na
7.78B
$ 0.91
$ 13.07
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-03-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 02-18-2025 12-31-2024 10-K
5 10-31-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 02-20-2024 12-31-2023 10-K
9 11-06-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 02-21-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 02-22-2022 12-31-2021 10-K
17 11-02-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 02-23-2021 12-31-2020 10-K
21 11-02-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 02-24-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-06-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 02-21-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 02-20-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-08-2017 06-30-2017 10-Q
35 05-09-2017 03-31-2017 10-Q
36 02-28-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-09-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 02-29-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-maintains-neutral-on-halozyme-therapeutics-raises-price-target-to-65

JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from ...

 morgan-stanley-maintains-overweight-on-halozyme-therapeutics-lowers-price-target-to-79

Morgan Stanley analyst Vikram Purohit maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and lowers the price t...

 hc-wainwright--co-reiterates-buy-on-halozyme-therapeutics-maintains-90-price-target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $...

 leerink-partners-upgrades-halozyme-therapeutics-to-market-perform-announces-70-price-target

Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Underperform to Market Perform and...

 hc-wainwright--co-maintains-buy-on-halozyme-therapeutics-raises-price-target-to-90

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the p...

 benchmark-maintains-buy-on-halozyme-therapeutics-raises-price-target-to-90

Benchmark analyst Robert Wasserman maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from...

 hc-wainwright--co-maintains-buy-on-halozyme-therapeutics-raises-price-target-to-85

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the p...

 morgan-stanley-maintains-overweight-on-halozyme-therapeutics-raises-price-target-to-80

Morgan Stanley analyst Vikram Purohit maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price t...

 jp-morgan-maintains-neutral-on-halozyme-therapeutics-raises-price-target-to-63

JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from ...

 jmp-securities-maintains-market-outperform-on-halozyme-therapeutics-raises-price-target-to-91

JMP Securities analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and raises the...

 hc-wainwright--co-maintains-buy-on-halozyme-therapeutics-raises-price-target-to-75

HC Wainwright & Co. analyst Mitchell Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the pric...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION